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Introduction
For decades, immunotherapy has been established therapy for the treatment of patients with mRCC. The cytokine IL2 was discovered in 1976 [1] , cloned in 1983 [2] and approved in 1992 by the US Food and Drug Administration for the treatment of patients with mRCC. This drug is curative for a small subset of patients with mRCC [3, 4] . Recently, the checkpoint inhibitor nivolumab demonstrated improved overall survival (OS) compared with contemporary standard therapy in second-line mRCC and received regulatory approval in 2015 [5] , but long-term follow-up data from responding patients are still pending.
The understanding of clear-cell RCC as a source of excess vascular endothelial growth factor (VEGF) production, due to inactivation of the von-Hipple Lindau tumor suppressor gene, has led to the development of anti-angiogenic therapy [6] . Sustained inhibition of VEGF with BEV, a humanized anti-VEGF monoclonal antibody, results in the regression of existing tumour microvasculature and inhibition in the formation of new vasculature [7, 8] . It may also revert tumor-associated immune suppression [9] , improve concomitant drug delivery into the tumour [10, 11] and permit efficient natural killer (NK) cell-mediated killing [12] .
BEV was the first anti-VEGF therapy to demonstrate clinical benefit in mRCC, and other tumours [13] . In mRCC patients, the addition of BEV to IFN compared with IFN alone produced statistically significant improvements in progression-free survival (PFS) and response rates [14, 15] . BEV in combination with low-dose [16] or high-dose IL2 [17] was feasible in non-randomized trials, with response rate and PFS at least as high as reported previously for the single agents.
BEV, IFN and IL2 all have stimulatory effects on the immune response and these three agents may have complementary and synergistic effects when combined [18] . We report the results from the Danish Renal Cancer Group (DaRenCa) study-1, a randomised phase II study to evaluate the efficacy and safety of BEV/IL2/IFN vs. IL2/IFN alone in patients with mRCC.
Patients and methods

Patients
DaRenCa-1 was an investigator-initiated, randomised, openlabel phase 2 study. The study was run within the multidisciplinary national DaRenCa group with patients enrolled at two centres in Denmark. Eligibility criteria were patients !18 years, with locally advanced or metastatic RCC, a clearcell histology component, no prior treatment, measurable disease per RECIST v.1.1 [19] , Memorial Sloan Kettering Cancer Center (MSKCC) favourable or intermediate risk [20] , Karnofsky Performance Status !70%, and adequate organ function (based on standard laboratory tests including hematology, serum chemistry, coagulation and urinanalysis). Exclusion criteria were brain metastases, spinal cord compression, uncontrolled hypertension, clinically significant cardiovascular or wound healing comorbidities, or corticosteroid requirement !10 mg/day. The study was approved by the Danish Medicines Agency, the Regional Research Ethics Committee, and the Danish Data Protection Agency; and adhered to the Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent. The study was registered at ClinicalTrials.gov, NCT01274273.
Patients were randomised 1:1 to receive IL2 and IFN-a or IL2 and IFN plus BEV. Randomisation was stratified by MSKCC risk group [20] utilizing a stratified permuted blocks design. Study personnel did not have access to the master list. This was an open-label study to allow appropriate management of adverse events.
Treatments
All cytokines were administered subcutaneously (s.c.) over 4-week cycles for up to a maximum of 9 cycles (i.e., 9 months): IFN was given as a fixed dose, 3.0 MIU s.c. once daily for 5 days per week commencing with a priming-week of daily IFN. IL2 was given 2.4 MIU/m 2 s.c. two times daily, 5 days per week, Weeks 1 and 2 every 4-week cycle. BEV at doses of 10 mg per kg of body weight was given every 2 weeks intravenously (i.v.) until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
Treatment interruptions, dose reductions or discontinuations were allowed to manage adverse events. In case of Grade 3 toxicity, with fatigue and fever as exceptions, therapy was delayed until toxicity was Grade 2 or less. For hepatic or renal Grade 3 toxicity, IL2 and IFN were dose reduced 50%. Intravenous (IV) fluid was allowed to prevent hypotension or renal toxicity. No dose reduction for BEV was permitted. In case of Grade 4 toxicity therapy was permanently discontinued. Crossover between treatment groups was not permitted. Physical examination, vital signs, laboratory assessments and urinalysis were conducted every 2 weeks for the first 4 weeks and then every 4 weeks thereafter. Adverse events were graded according to CTCAE v.3Á0.CT were conducted at screening and every 12 weeks for the first 2 years and then every 6-months thereafter. Tumour response and progression were assessed by local radiologists according to Response Evaluation Criteria in Solid Tumours (RECIST) v.1Á1 [19] . Patients were not allowed to continue treatment if clinical benefit and/or biochemical improvements were seen in spite of radiological progression according to RECIST 1.1. Pseudoprogression was newer a challenge.
Endpoints
The primary endpoint was PFS, defined as the time from randomisation to date of progression per RECIST v.1Á1 or death. Secondary endpoints were objective response rate (ORR), OS, time-to-treatment failure (TTF), tolerability, frequency of surgical resection of residual disease and frequency of NED. TTF was defined as time from randomisation to date of disease progression, death, withdrawal of treatment due to adverse events or laboratory abnormality, or withdrawn informed consent. Overall survival was defined as the time from randomisation to date of death from any cause, and ORR was defined as the proportion of patients experiencing best objective response as complete or partial response per RECIST 1Á1.
Statistical analysis
The study was designed to provide adequate power for detecting a statistically significant difference in the primary endpoint of PFS. Assuming a median progression-free survival of 5 months in the IL2/IFN arm and 9 months in the IL2/IFN/BEV arm, corresponding to an 80% improvement in PFS, then 85 events were required to achieve overall 80% power of the log rank test at a two-sided overall 5% a-level. In order to see the required number of events within the planned study duration a total of 118 patients were required. Median duration of PFS, TTF and OS, corresponding 95% confidence intervals, were estimated by the Kaplan-Meier method. All analyses were conducted using SPSS V R software (IBM Corporation, Armonk, NY, USA) v.20. (Figure 1(C) ).
Results
Patient characteristics
Similar proportions of patients in the IL2/IFN/BEV and IL2/ IFN groups had subsequent systemic anticancer therapy following study treatment discontinuation with no statistically significant difference between subgroups (85 versus 78%) ( phase III trial, demonstrated similar improvements in PFS (10.2 versus 5.4 months) and RR (31 versus 13%) [14] . In both trials, however, BEV/IFN therapy did not improve OS statistically significant [22, 23] . Our data are in line with these results, but did not add efficacy further, despite the addition of IL2. Our data are also in line with the non-randomized experiences with low-dose and high-dose IL2 in combination with BEV [16, 17] ; BEV in combination with high-dose IL2 did not increase durable responses [17] , as also seen in our study. With the extended follow-up of median 64 months, most patients eventually progressed with this low-dose IL2 regimen. At study closure, 7 patients (6%) had NED. BEV has been used in combination with various agents for first-line treatment in clear-cell mRCC, without adding efficacy. The temsirolimus/BEV combination versus IFN/BEV was not superior in the INTORACT study [24] or in the TORAVA study, where excess toxicity of the temsirolimus/BEV combination resulted in $50% of patients had to stop treatment [25] . The efficacy of everolimus/BEV and IFN/BEV was similar in the RECORD 2 study [26] . PFS was similar between BEV monotherapy (7.5 months) and BEV/temsirolimus, BEV/sorafenib, or BEV/IFN in the four-arm BEST trial [27] . The combination of BEV and sunitinib resulted in excess toxicity and the combination was not considered feasible for further development [28, 29] . Randomized phase III data for the combination of BEV and check-point inhibitors are pending.
IL2 has consistently resulted in durable complete responses and cure in a small subset of $5% of patients [3, 30] . However, the toxicity associated with the drug has hindered the wide-use of IL2 and restricted its use to experienced centres. IL2 has been used in combination with various agents for first-line treatment in mRCC, without adding efficacy. IL2/histamine did not add efficacy compared with IL2 alone [31] . IL2 alone, or combined with IFN, compared with the hormone drug medroxyprogesterone resulted in similar OS in intermediate-prognosis mRCC patients [32] . Combination therapy of IL2/IFN and 5-fluorouracil (5-FU) chemotherapy did not improve efficacy compared with IFN alone [33] . IL2/sorafenib resulted in similar survival rates as sorafenib alone [34] . In essence, single agent BEV and single agent IL2 have demonstrated clinical efficacy in patients with mRCC, but attempts to improve efficacy, in terms of improved OS, by combination therapy with other drugs, have so far failed, including our study.
Toxicities did not exceed those expected from each agent alone. The most common adverse events were typical of those observed with these drugs including fatigue, flu-like symptoms, diarrhoea, nausea, decreased appetite, and hypertension [6] . The lower incidence of thrombosis in the BEV arm is surprising, and was probably obtained by chance; it emphasizes, however, that the combination therapy was safe. Averse events were managed with supportive care in both treatment groups.
Subsequent anticancer therapy was balanced between treatment groups after study treatment discontinuation. Therefore, these factors are deemed unlikely to have biased the OS results towards one treatment group. In addition, treatment crossover was not allowed after determination of the primary endpoint of PFS enabling robust assessment of OS. Our data emphasizes that IL2 therapy does not compromise subsequent therapy, or clinical benefit, from subsequent therapy.
Eligibility criterion for the present study was treatment naïve mRCC patients that were not candidates for surgery. The tumour regression following systemic therapy enabling surgery of residual disease in 17.0% of patients should be noted, resulting in clinical meaningful benefit in a substantial part of patients. These benchmarks data provide perspective when interpreting the results from the next generation of immunotherapies, the check-point inhibitors. Identification of patients who will benefit from immunotherapy is crucial. This study was accompanied by sampling of blood, tumour and imaging biomarkers for predictive studies, which will be published separately. Functional imaging may represent a tool for selecting patients that will benefit, or not benefit, from therapy [35] .
In conclusion, the addition of BEV, an inhibitor of VEGF, to IL2-based immunotherapy was not associated with improvements in PFS, OS, TTF, ORR, surgery of residual disease, or patients with NED. This combination cannot be recommended for treatment in patients with mRCC.
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